Literature DB >> 23183441

Inhaled microparticles containing clofazimine are efficacious in treatment of experimental tuberculosis in mice.

Rahul Kumar Verma1, Willem A Germishuizen, M Portia Motheo, Atul Kumar Agrawal, Amit Kumar Singh, Mradul Mohan, Pushpa Gupta, Umesh Datta Gupta, Moloko Cholo, Ronald Anderson, P Bernard Fourie, Amit Misra.   

Abstract

Inhalable clofazimine-containing dry powder microparticles (CFM-DPI) and native clofazimine (CFM) were evaluated for activity against Mycobacterium tuberculosis in human monocyte-derived macrophage cultures and in mice infected with a low-dose aerosol. Both formulations resulted in 99% killing at 2.5 μg/ml in vitro. In mice, 480 μg and 720 μg CFM-DPI inhaled twice per week over 4 weeks reduced numbers of CFU in the lung by as much as log(10) 2.6; 500 μg oral CFM achieved a log(10) 0.7 reduction.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23183441      PMCID： PMC3553724          DOI： 10.1128/AAC.01897-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  Handbook of anti-tuberculosis agents. Introduction.

Authors: 
Journal:  Tuberculosis (Edinb)       Date:  2008-03       Impact factor: 3.131

Review 2.  Antimycobacterial activities of riminophenazines.

Authors:  V M Reddy; J F O'Sullivan; P R Gangadharam
Journal:  J Antimicrob Chemother       Date:  1999-05       Impact factor: 5.790

Review 3.  Clofazimine: current status and future prospects.

Authors:  Moloko C Cholo; Helen C Steel; P B Fourie; Willem A Germishuizen; Ronald Anderson
Journal:  J Antimicrob Chemother       Date:  2011-10-20       Impact factor: 5.790

4.  In vitro and in vivo activity of clofazimine against Mycobacterium tuberculosis persisters.

Authors:  J Xu; Y Lu; L Fu; H Zhu; B Wang; K Mdluli; A M Upton; H Jin; M Zheng; W Zhao; P Li
Journal:  Int J Tuberc Lung Dis       Date:  2012-06-12       Impact factor: 2.373

5.  Metabolism of clofazimine in leprosy patients.

Authors:  P C Feng; C C Fenselau; R R Jacobson
Journal:  Drug Metab Dispos       Date:  1981 Nov-Dec       Impact factor: 3.922

6.  A hand-held apparatus for "nose-only" exposure of mice to inhalable microparticles as a dry powder inhalation targeting lung and airway macrophages.

Authors:  Jatinder Kaur; Pavan Muttil; Rahul Kumar Verma; Kaushlendra Kumar; Awadh Bihari Yadav; Rolee Sharma; Amit Misra
Journal:  Eur J Pharm Sci       Date:  2008-03-04       Impact factor: 4.384

7.  Antituberculosis activities of clofazimine and its new analogs B4154 and B4157.

Authors:  V M Reddy; G Nadadhur; D Daneluzzi; J F O'Sullivan; P R Gangadharam
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

8.  Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model.

Authors:  L Garcia-Contreras; J Fiegel; M J Telko; K Elbert; A Hawi; M Thomas; J VerBerkmoes; W A Germishuizen; P B Fourie; A J Hickey; D Edwards
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191
  8 in total
  15 in total

1.  Inhaled Pyrazinoic Acid Esters for the Treatment of Tuberculosis.

Authors:  E F Young; E Perkowski; S Malik; J D Hayden; P G Durham; L Zhong; J T Welch; Miriam S Braunstein; Anthony J Hickey
Journal:  Pharm Res       Date:  2016-06-28       Impact factor: 4.200

Review 2.  Advances in the development of new tuberculosis drugs and treatment regimens.

Authors:  Alimuddin Zumla; Payam Nahid; Stewart T Cole
Journal:  Nat Rev Drug Discov       Date:  2013-05       Impact factor: 84.694

Review 3.  Inhalation of sustained release microparticles for the targeted treatment of respiratory diseases.

Authors:  Gauthami Pulivendala; Swarna Bale; Chandraiah Godugu
Journal:  Drug Deliv Transl Res       Date:  2020-04       Impact factor: 4.617

4.  The Physicochemical Basis of Clofazimine-Induced Skin Pigmentation.

Authors:  Mikhail D Murashov; Vernon LaLone; Phillip M Rzeczycki; Rahul K Keswani; Gi S Yoon; Sudha Sud; Walajapet Rajeswaran; Scott Larsen; Kathleen A Stringer; Gus R Rosania
Journal:  J Invest Dermatol       Date:  2017-10-16       Impact factor: 8.551

5.  Respirable Clofazimine Particles Produced by Air Jet Milling Technique Are Efficacious in Treatment of BALB/c Mice with Chronic Mycobacterium tuberculosis Infection.

Authors:  Ashlee D Brunaugh; Amanda Walz; Zachary Warnken; Camron Pearce; Juan Munoz Gutierrez; John J Koleng; Hugh D C Smyth; Mercedes Gonzalez-Juarrero
Journal:  Antimicrob Agents Chemother       Date:  2022-08-09       Impact factor: 5.938

6.  Clofazimine for Treatment of Extensively Drug-Resistant Pulmonary Tuberculosis in China.

Authors:  Qingfeng Wang; Yu Pang; Wei Jing; Yufeng Liu; Na Wang; Hongyun Yin; Qing Zhang; Zhizhong Ye; Min Zhu; Fujian Li; Ping Liu; Tingting Wu; Wei Chen; Wei Wu; Zhihua Qin; Chao Qiu; Qunyi Deng; Tao Xu; Jing Wang; Ru Guo; Yadong Du; Jun Wang; Hairong Huang; Xiaohong Chen; Naihui Chu
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

Review 7.  Why Wait? The Case for Treating Tuberculosis with Inhaled Drugs.

Authors:  Miriam Braunstein; Anthony J Hickey; Sean Ekins
Journal:  Pharm Res       Date:  2019-10-24       Impact factor: 4.200

Review 8.  Targeted pulmonary delivery of inducers of host macrophage autophagy as a potential host-directed chemotherapy of tuberculosis.

Authors:  Anuradha Gupta; Amit Misra; Vojo Deretic
Journal:  Adv Drug Deliv Rev       Date:  2016-01-29       Impact factor: 15.470

9.  Efficacy of moxifloxacin & econazole against multidrug resistant (MDR) Mycobacterium tuberculosis in murine model.

Authors:  U D Gupta; N Vemuri; P Gupta; V Kumar; P Tanushree; G K Khuller
Journal:  Indian J Med Res       Date:  2015-09       Impact factor: 2.375

Review 10.  Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?

Authors:  Wing Wai Yew; Won-Jung Koh
Journal:  Korean J Intern Med       Date:  2015-12-28       Impact factor: 2.884
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.